Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML

Authors:

Abstract
Key Points DNMT3AR882, TET2, ASXL1, and SRSF2 mutations identified at the time of diagnosis are associated with delayed count recovery. Persistence of preleukemic mutations in remission at high variant allele frequency is associated with delayed count recovery.

This publication has 19 references indexed in Scilit: